skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Pentavalent (/sup 99m/Tc)DMSA, (/sup 131/I)MIBG, and (/sup 99m/Tc)MDP--an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid

Journal Article · · J. Nucl. Med.; (United States)
OSTI ID:5400946

Nine patients with histologically proven medullary carcinoma of the thyroid (MCT) were imaged using pentavalent (/sup 99m/Tc)dimercaptosuccinic acid ((V)DMSA), (/sup 131/I) metaiodobenzylguanidine (MIBG) and (/sup 99m/Tc)methylene diphosphonate (MDP). Technetium-99m (V)DMSA demonstrated most of the tumor sites in eight patients with proven metastases, with an overall sensitivity of 95% in lesion detection. Iodine-131 MIBG showed definite uptake in some of the tumor sites in three of the nine patients imaged, with equivocal uptake seen in a further one patient, with sensitivity of only 11% for lesion detection. Technetium-99m MDP demonstrated bony metastases only, in four of the patients imaged yielding a sensitivity of 61%. Technetium-99m (V)DMSA has been demonstrated in this study to be a useful imaging agent in patients with MCT, showing uptake in significantly more lesions and with better imaging qualities than (/sup 131/I)MIBG, and with the ability to detect soft tissue as well as bony metastases.

Research Organization:
Guy's Hospital, London, England
OSTI ID:
5400946
Journal Information:
J. Nucl. Med.; (United States), Vol. 29:1
Country of Publication:
United States
Language:
English